These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16567704)

  • 1. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort.
    Cherry CL; Skolasky RL; Lal L; Creighton J; Hauer P; Raman SP; Moore R; Carter K; Thomas D; Ebenezer GJ; Wesselingh SL; McArthur JC
    Neurology; 2006 Mar; 66(6):867-73. PubMed ID: 16567704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlates of epidermal nerve fiber densities in HIV-associated distal sensory polyneuropathy.
    Zhou L; Kitch DW; Evans SR; Hauer P; Raman S; Ebenezer GJ; Gerschenson M; Marra CM; Valcour V; Diaz-Arrastia R; Goodkin K; Millar L; Shriver S; Asmuth DM; Clifford DB; Simpson DM; McArthur JC;
    Neurology; 2007 Jun; 68(24):2113-9. PubMed ID: 17562831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV neuropathy natural history cohort study: assessment measures and risk factors.
    Simpson DM; Kitch D; Evans SR; McArthur JC; Asmuth DM; Cohen B; Goodkin K; Gerschenson M; So Y; Marra CM; Diaz-Arrastia R; Shriver S; Millar L; Clifford DB;
    Neurology; 2006 Jun; 66(11):1679-87. PubMed ID: 16769940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age and height predict neuropathy risk in patients with HIV prescribed stavudine.
    Cherry CL; Affandi JS; Imran D; Yunihastuti E; Smyth K; Vanar S; Kamarulzaman A; Price P
    Neurology; 2009 Jul; 73(4):315-20. PubMed ID: 19636052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006.
    Smyth K; Affandi JS; McArthur JC; Bowtell-Harris C; Mijch AM; Watson K; Costello K; Woolley IJ; Price P; Wesselingh SL; Cherry CL
    HIV Med; 2007 Sep; 8(6):367-73. PubMed ID: 17661844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a clinical screening tool for HIV-associated sensory neuropathies.
    Cherry CL; Wesselingh SL; Lal L; McArthur JC
    Neurology; 2005 Dec; 65(11):1778-81. PubMed ID: 16344522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
    Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
    Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting.
    Manosuthi W; Prasithsirikul W; Chumpathat N; Suntisuklappon B; Athichathanabadi C; Chimsuntorn S; Sungkanuparph S
    Int J Infect Dis; 2008 Nov; 12(6):582-6. PubMed ID: 18337140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study.
    Herrmann DN; McDermott MP; Sowden JE; Henderson D; Messing S; Cruttenden K; Schifitto G
    Neurology; 2006 Mar; 66(6):857-61. PubMed ID: 16567702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
    Smith CJ; Olsen CH; Mocroft A; Viard JP; Staszewski S; Panos G; Staub T; Blaxhult A; Vetter N; Lundgren JD
    AIDS; 2008 Jan; 22(1):47-56. PubMed ID: 18090391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection.
    Simpson DM; Tagliati M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):153-61. PubMed ID: 7749792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.
    Borghi V; Puoti M; Mussini C; Bellelli S; Angeletti C; Sabbatini F; Prati F; Cossarizza A; Esposito R
    Antivir Ther; 2008; 13(8):1057-65. PubMed ID: 19195331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV neuropathy in South Africans: frequency, characteristics, and risk factors.
    Maritz J; Benatar M; Dave JA; Harrison TB; Badri M; Levitt NS; Heckmann JM
    Muscle Nerve; 2010 May; 41(5):599-606. PubMed ID: 20229576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.
    Pettersen JA; Jones G; Worthington C; Krentz HB; Keppler OT; Hoke A; Gill MJ; Power C
    Ann Neurol; 2006 May; 59(5):816-24. PubMed ID: 16634006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.